Advanced and Metastatic Triple Negative Breast Cancer-Potential New Treatment

Area of Science:

• Oncology
• Clinical Trials Research

Background:

• Breast cancer is a leading cause of cancer death in women globally, with over 2 million diagnoses in 2022.
• Triple-negative breast cancer (TNBC) is an aggressive subtype, accounting for 10-20% of cases, and has a high risk of metastasis (40%).

Purpose of the Study:

• To present current clinical trials investigating novel treatments for advanced and metastatic TNBC.
• To consolidate information on emerging therapeutic strategies for TNBC.

Main Methods:

• Systematic search of the clinicaltrials.gov database.
• Inclusion of Phase I and II Randomized Controlled Trials (RCTs).
• Focus on primary endpoints such as objective response rate, adverse events, progression-free survival, and pathologic complete response.

Main Results:

• Identified and summarized ongoing clinical trials for advanced and metastatic TNBC.
• Highlighted key endpoints being evaluated in these trials, including efficacy and safety metrics.
• Acknowledged the preliminary nature of Phase I/II trial data.

Conclusions:

• Current clinical trials are exploring innovative treatments for advanced and metastatic TNBC.
• Future results from these trials are crucial for informing clinical guidelines and improving patient care for TNBC.
• Further investigation is needed to fully understand the implications of these new therapies.